Urinary tissue factor: A potential marker of disease

Journal of Pathology

Volumn 188, Issue 1, 1999, Pages 3-8

  Lwaleed, Bashir A ^a,c   Bass, Paul S ^a   Francis, John L ^b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b Walt Disney Mem Cancer Inst F   (United States)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Cancer; Renal disorders; Source and origin; Tissue factor; Tumour biology; Urinary tissue factor

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOTOXIC AGENT; PROCOAGULANT; THROMBOPLASTIN;

AGE; ANGIOGENESIS; BLOOD CLOTTING; CANCER; CANCER CELL CULTURE; DISEASE MARKER; GLOMERULONEPHRITIS; HUMAN; MONOCYTE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SMOKING; TUMOR ASSOCIATED LEUKOCYTE; URINE LEVEL;

AGE FACTORS; BLOOD COAGULATION; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY NEOPLASMS; SEX FACTORS; THROMBOPLASTIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0032917998     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199905)188:1<3::AID-PATH282>3.0.CO;2-T     Document Type: Review

References (126)

1. Lerner RG, Goldstein R, Cummings G. Stimulation of human leukocyte thromboplastic activity by endotoxin. Proc Soc Exp Biol Med 1971; 138: 145-148.
2. Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Clin Med 1981; 98: 917-928.
3. Fleck RA, Vijaya Mohan Rao L, Rapaport SI, Varki N. Localization of human tissue factor antigen by immuno-staining with monospecific, polyclonal anti-human tissue factor antibody. Thromb Res 1990; 59: 421-437.
4. Callander NS, Varki N, Rao LV. Immunohistochemical identification of tissue factor in solid tumours. Cancer 1992; 70: 1194-1201.
5. Nemerson Y, Pitlick FA. The tissue factor pathway of blood coagulation. Prog Haemost Thromb 1972; 1: 1-37.
6. Bach RR, Nemerson Y, Konigsberg WK. Purification and characterization of bovine tissue factor. J Biol Chem 1981; 256: 8324-8331.
7. Broze GJ, Leykam JE, Schwartz BD, Miletich JP. Purification of human brain tissue factor. J Biol Chem 1985; 260: 10 917-10 920.
8. Guha A, Bach RR, Konigsberg W, Nemerson Y. Affinity purification of human tissue factor. Interaction of factor VII and tissue factor in detergent micelles. Proc Natl Acad Sci U S A 1986; 83: 299-302.
9. Bach RR. Initiation of coagulation by tissue factor. CRC Crit Rev Biochem 1988; 23: 338-368.
10. Kang S, Niemetz J. Purification of human brain tissue factor. Thromb Haemost 1988; 59: 400-403.
11. Nemerson Y. Tissue factor: then and now. Thromb Haemost 1995; 74: 180-184.
12. Maynard JR, Heckman CA, Pitlick EA, Nemerson Y. Association of tissue factor activity with the surface of cultured cells. J Clin Invest 1975; 55: 814-824.
13. Maynard JR, Dreyer BA, Stemerman MB, Pitlick FA. Tissue factor coagulation activity of cultured human endothelial and smooth muscle cells and fibroblasts. Blood 1977; 50: 387-396.
14. Weiss HJ, Turitto VT, Baumgartner HR, Nemerson Y, Hoffman T. Evidence for the presence of tissue factor activity on sub-endothelium. Blood 1989; 73: 968-975.
15. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal blood vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A 1989; 86: 2839-2843.
16. Edwards RL, Rickles FR, Bobrove AM. Mononuclear cell tissue factor: cell of origin and requirements for activation. Blood 1979; 54: 359-370.
17. Drake TA, Morrissey JH, Edgington TA. Selective cellular expression of tissue factor in human tissues: implication for disorders of haemostasis and thrombosis. Am J Pathol 1989; 134: 1087-1097.
18. Drake T, Ruf W, Morrissey JH, Edgington T. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol 1989; 109: 389-395.
19. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A 1986; 83: 3460-3464.
20. Østerud B, Flaegstad T. Increased thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983; 49: 5-7.
21. Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
22. Carty N, Taylor I, Roath OS, El-Baruni K, Francis JL. Urinary tissue factor activity in malignancy. Thromb Res 1990; 57: 473-478.
23. Carty N. Taylor I, Roath OS, El-Baruni K, Francis JL. Urinary tissue factor activity in colorectal disease. Br J Surg 1990; 77: 1091-1094.
24. Iijima K, Fukada C, Nakumara K. Measurements of tissue factor like-activity in plasma of patients with DIC. Thromb Res 1991; 61: 29-38.
25. Adamson AS, Francis JL, Roath OS, Witherow RO'N, Snell ME. Urinary tissue factor levels in transitional cell carcinoma of the bladder. J Urol 1992; 148: 449-452.
26. Adamson AS, Francis JL, Witherow RO'N, Snell ME. Urinary tissue factor levels in prostatic carcinoma: a potential marker of metastatic spread. Br J Urol 1993; 71: 587-592.
27. Carvalho MG, Francis JL. Monocyte tissue factor levels in normal subjects and patients with cancer (Abstract). Thromb Haemost 1993; 69: 601.
28. Francis JL, Carvalho M, Francis DA. The clinical value of tissue factor assays. Blood Coag Fibrinol 1995; 6: 37-44.
29. Fareed J, Callas DD, Hoppensteadt D, Bermes EW. Tissue factor antigen levels in various biological fluids. Blood Coag Fibrinol 1995; 6: 32-36.
30. Lwaleed BA, Francis JL, Chisholm M. Urinary tissue factor level in neoplastic diseases (Abstract). Br J Haematol 1996; 93: 103.
31. Lwaleed BA, Chisholm M, Francis JL. Elevated blood monocyte tissue factor levels in patients with cancer (Abstract). Br J Cancer 1997; 75: 45.
32. Rodgers GM. Haemostatic properties of normal and perturbed vascular cells. FASEB J 1988; 2: 116-123.
33. Cybulsky MI, Chan MKW, Movat HZ. Acute inflammation and micro-thrombosis induced by endotoxin, interleukin-1, and tumour necrosis factor and their implications in Gram-negative infection. Lab Invest 1988; 58: 365-378.
34. Nemerson Y, Bach R. Tissue factor revisited. Prog Hemost Thromb 1982; 6: 237-261.
35. Bangham AD. A correlation between surface charge and coagulant action of phospholipids. Nature 1961; 192: 1197-1198.
36. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumour derived-polypeptide which induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535-1545.
37. Dvorak HF, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by micro-vascular permeability. Science 1985; 227: 1059-1062.
38. Contrino J, Hair G, Kreutzer D, Rickles FR. In situ detection of expression of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast tissue. Nature Med 1996; 2: 209-215.
39. 3 integrins, osteopontin and thrombin. Am J Pathol 1996; 149: 293-305.
40. Folkman J. Tumour angiogenesis and tissue factor. Nature Med 1996; 2: 167-168.
41. Kadish JL, Butterfield CE, Folkman J. The effect of fibrin on cultured vascular endothelial cells. Tissue Cell 1979; 11: 99-108.
42. Dejana E, Lampugna MG, Giorgi M, Gaboli M, Marchisi PC. Fibrinogen induces endothelial-cell adhesion and spreading via the release of endogenous matrix proteins and the recruitment of more than one integrin receptor. Blood 1990; 75: 1509-1517.
43. Dvorak HF, Nagy JA, Berse B, et al. Vascular permeability factor, fibrin, and the pathogenesis of tumour stroma formation. Ann NY Acad Sci 1992; 667: 101-111.
44. Nakagawa M, Emoto A, Nasu N, et al. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer. J Urol 1997; 157: 1260-1265.
45. Hayes M, Duffy P, Cooper A, Smart C. Membrane charge and phospholipid asymmetry in multidrug resistance (Abstract). Cytotechnology 1996; 19: 287.
46. Satta N, Toti F, Feugeas O, et al. Monocyte vesiculation. A mechanism for dissemination of membrane-associated procoagulant activity and adhesion molecules after stimulation by LPS. J Immunol 1994; 153: 3245-3255.
47. Hu T, Bach RR, Horton R, Konigsberg WH, Todd MB. Synthesis of tissue factor messenger RNA and procoagulant activity in breast cancer cells in response to serum stimulation. Thromb Res 1993; 72: 155-168.
48. Lwaleed BA, Hayes M, Cooper A, Francis JL, Chisholm M. Functional and exposed tissue factor in drug resistant cancer cells (Abstract). Blood 1996; 88: 68.
49. Grunke W. Studien über die Bluterinnung mit besonderer Berücksichtigung der Haemophilie. I. Mitteilung: Einfluss des Harnes auf die Gerinnung haemophilen Blutes. Blutes Z Ges Exp Med 1835; 96: 512-516.
50. Tocantins LM, Lindquist JN. Thomboplastic activity of the urine. Proc Soc Exp Biol N Y 1947; 65: 44-49.
51. von Kaulla KN. Urine adsorbed with fibrinolytic and thromboplastic properties (Abstract). J Lab Clin Med 1954; 44: 944.
52. von Kaulla KN. On purification and properties of urine thromboplastin. Proceedings of the Sixth Congress of the International Society of Hematology, Boston, 1965. New York: Grune & Stratton, 1958; 611.
53. von Kaulla KN, von Kaulla E. Inactivation of pathological inhibitors of intrinsic thromboplastin by procoagulant from human urine. Acta Haematol 1963; 30: 25-34.
54. von Kaulla KN. Extraction and concentration of thromboplastic material from human urine. Proc Soc Exp Biol Med N Y 1956; 91: 543-545.
55. Matsumura T, Hutt MP, von Kaulla KN. Urinary procoagulant excretion and its relation to kidney function. Nephron 1970; 7: 165-177.
56. Caldwell J, von Kaulla KN, von Kaulla E, Seegers WH. Procoagulant material from human urine in prothrombin activation. Thromb Diath Haemorrh 1963; 9: 53-61.
57. Aoki N, von Kaulla KN. The procoagulant in human urine: purification, assay and some biochemical and physiological properties. Thromb Diath Haemorrh 1966; 9: 586-605.
58. Joist H, Alkjaersig N. Uroplastin, its nature and its excretion pattern in health and certain disease states. Thromb Diath Haemorrh 1967; 18: 425-132.
59. Kurosawa S, Matsuda M, Aoki N. Urinary procoagulant behaves as tissue factor by promoting factor VIIa-catalyzed activation of factor X. Thromb Res 1984; 33: 595-606.
60. Wiggins R, Glatfelter A, Kshirsagar B, Beals T. Lipid vesicles and their association with procoagulant activity and glomeruli of rabbits with nephrotoxic nephritis. Lab Invest 1987; 56: 264-272.
61. Zacharski LR, Rosenstein R, Phillips PG. Concanavalin A inhibition of tissue factor (thromboplastin) activity. Blood 1974; 44: 783-787.
62. Matsumura T, von Kaulla KN. Procoagulant content of human urine in health and disease. Am J Clin Pathol 1968; 50: 198-210.
63. Matsuda M, Aoki N. Purification and characterization of procoagulant in human urine. Thromb Res 1978; 13: 311-324.
64. Fisher KL, Gorman CM, Vehar GA, O'Brien DP, Lawn RM. Cloning and expression of human tissue factor cDNA. Thromb Res 1987; 48: 89-99.
65. Wiggins RC, Glatfelter A, Kshirsagar B, Brukman J. Procoagulant activity in normal human urine associated with sub-cellular particles. Kidney Int 1986; 29: 591-597.
66. Carty N. The coagulation system and malignancy. Master of Surgery Thesis. Southampton University, 1990.
67. Lwaleed BA, Chisholm M, Francis JL. Development and validation of an assay for urinary tissue factor activity. J Clin Pathol 1999 (in press).
68. Lwaleed BA, Francis JL, Chisholm M. Functional, structural properties and cells of origin of urinary tissue factor (Abstract). Br J Haematol 1998; 102; 263.
69. Funakoshi T, Heimark RL, Hendrickson LE, McMullen BA, Fujikawa K. Human placental anticoagulant protein: isolation and characterization. Biochemistry 1987; 26: 5572-5578.
70. Carvalho MG. Monocyte tissue factor in malignancy. PhD thesis. Southampton University, 1995.
71. Lwaleed Ba, Bass PS, Rogerson ME, Francis JL, Chisholm M. Effect of kidney function and disease status on urinary tissue factor measurements. J Clin Pathol 1998; 51: 234-237.
72. Neale TJ, Carson SD, Tipping PG, Holdsworth SR. Participation of cell-mediated immunity in deposition of fibrin in glomerulonephritis. Lancet 1988; 2: 421-424.
73. Adamson AS. Procoagulants, coagulopathy and prostate cancer. Master of Surgery thesis. Southampton University, 1992.
74. Bukovsky A, Labarrere CA, Haag B, Carter C, Faulk WP. Tissue factor in normal and transplanted human kidney. Transplantation 1992; 54: 644-650.
75. Matsumura T, Hutt MP, von Kaulla KN. Urinary procoagulant excretion in experimental renal disease. Proc Soc Exp Biol Med 1968; 127: 147-153.
76. Matsuda M, Aoki, N, Kawaoi A. Localization of urinary procoagulant in human kidney. Kidney Int 1979; 15: 612-617.
77. Lwaleed BA, Francis JL, Chisholm M. Monocyte tissue factor level in benign and malignant diseases (Abstract). Br J Haematol 1996; 93: 19.
78. Lwaleed BA, Francis JL, Chisholm M. The validity of tissue factor assay as a diagnostic tool for cancer: correlation between urinary tissue factor and monocyte tissue factor activity (Abstract). Br J Haematol 1998; 101: 56.
79. Colucci M, Semeron N, Montemuro P, et al. Urinary procoagulant and fibrinolytic activity in human glomerulonephritis. Relationship with renal function. Kidney Int 1991; 39: 1213-1217.
80. Lwaleed BA, Bass PS, Chisholm M, Francis JL. Urinary tissue factor levels in glomerulonephritis: a potential marker of glomerular injury. J Clin Pathol 1997; 50: 336-340.
81. Lwaleed BA, Chisholm M, Francis JL. Urinary tissue factor levels in patients with breast and colorectal cancer. J Pathol 1999 (in press).
82. Morrell MT, Dunnill MS. The post-mortem incidence of pulmonary embolism in a hospital population. Br J Surg 1968; 55: 347-352.
83. Vessey MP, Doll R. Investigation of relation between use of oral contraceptive and thrombotic disease: a further report. B M J 1969; 2: 651-657.
84. Kakkar VV, Howe CT, Nicolaides AN, Renney JTG, Clarke MB. Deep vein thrombosis of the leg. Is there a high risk group? Am J Surg 1970; 120: 527-530.
85. Hamilton PJ, Allardyce M, Ogston D, Dawson AA, Douglas AS. The effect of age upon the coagulation system. J Clin Pathol 1974; 27: 980-982.
86. Dodds WJ, Moynihan AC, Benson RE, Hall CA. The value of age-and-sex matched controls for coagulation studies. Br J Haematol 1975; 29: 305-317.
87. Cawkwell RD. Patient's age and the activated thromboplastin time test. Thromb Haemost 1978; 39: 780-783.
88. Coon WW. Epidemiology of venous thromboembolism. Ann Surg 1977; 186: 149-164.
89. Simpson NE, Biggs R. The inheritance of Christmas factor. Br J Haematol 1962; 8: 191-203.
90. 14C in subjects with coronary thrombosis. Thromb Diath Haemorrh 1968; 20: 31-43.
91. Lester RH, Elston RC, Graham JB. Variations in levels of blood clotting factors IX and X in a population of normal men: possible genetics polymorphisms. Am J Hum Genet 1972; 24: 168-180.
92. Scarabin PV, Vissac AM, Kirzin JM, et al. Population correlates of coagulation factor VII. Importance of age, sex and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol 1996; 16: 1170-1176.
93. Calmus I, Robert A. Increased monocyte procoagulant activity with age. Thromb Res 1986; 41: 133-136.
94. Parmar J, Taylor I, Roath OS, Francis JL. Procoagulant activity in whole blood from patients with breast and colorectal cancer. Blood Coag Fibrinol 1990; 1: 127-132.
95. Edwards RL, Rickles FR. The role of leukocytes in the activation of blood coagulation. Semin Haematol 1992; 29: 202-212.
96. Cooperberg AA, Teitelbaum J. The concentration of anti-haemophilic globulin (AHG) related to age. Br J Haematol 1960; 6: 281-287.
97. Pitney WR, Kirk RL, Arnold BJ, Stenhouse NS. Plasma anti-haemophilic factor (factor VIII) concentrations in normal families. Br J Haematol 1962; 8: 421-428.
98. Preston AE, Barr A. The plasma concentration of factor VIII in the normal population. II. The effects of age, sex and blood group. Br J Haematol 1964; 10: 238-245.
99. Kerr CB, Preston AE, Barr A, Biggs R. Further studies on the inheritance of factor VIII. Br J Haematol 1966; 12: 212-233.
100. Francis JL, Francis DA, Gunathilagan GJ. Assessment of hypercoagulability in patients with cancer using the Sonoclot Analyzer and thromboelastography. Thromb Res 1994; 74: 335-346.
101. Lwaleed BA, Chisholm M, Francis JL. The significance of measuring monocyte tissue factor in patients with breast and colorectal cancer. Br J Cancer 1999 (in press).
102. Vassali JD, Hamilton J, Reich E. Macrophage plasminogen activator modulation of enzyme production by anti-inflammatory steroids, mitotic inhibitors and cyclic nucleotides. Cell 1976; 8: 271-281.
103. Prydz H, Lyberg T. Effect of some drugs on thromboplastin (factor III) activity of human monocytes in vitro. Biochem Pharmacol 1980; 29: 9-18.
104. Muhlfelder TW, Niemetz J, Kang S. Glucocorticoids inhibit the generation of leukocyte procoagulant (tissue factor) activity. Blood 1982; 60: 1169-1172.
105. Calsen E, Prydz H. Enhancement of procoagulant activity in stimulated mononuclear blood cells and monocytes by cyclosporin. Transplantation 1987; 43: 453-548.
106. Walsh J, Wheeler HR, Carolyn L. Modulation of tissue factor on human monocytes by cisplatin and adriamycin. Br J Haematol 1992; 81: 480-488.
107. Rickles FR, Edwards RL. Activation of blood coagulation of cancer: Trousseau's syndrome revisited. Blood 1983; 62: 14-31.
108. Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1995; 54: 475-479.
109. Green D, Ruth KJ, Folsom AR, Liu K. Hemostatic factors in the coronary artery risk development in young adults (CARDIA) study. Arterioscler Thromb 1994; 14: 686-693.
110. Gader A, Bahakim H, Awadalla S, Malaika S. Ethnic variations in the haemostatic system: comparison between Arabs, Westerns (Europeans and Americans), Asians and Africans. Blood Coagul Fibrinol 1995; 6: 537-542.
111. Palmer HE, Jurd KM, Hunt BJ, et al. Thrombophilic factors in ischaemic and non-ischaemic idiopathic retinal vasculitis. Eye 1995; 9: 507-512.
112. Morrissey JH, Macik BG, Neuenchwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-744.
113. Merceline-Roumans PE, Ubachs JM, van Wersch JW. Coagulation and fibrinolysis in smoking and nonsmoking pregnant women. Br J Obstet Gynaecol 1996; 103: 789-794.
114. Cortellaro M, Boschetti C, Cofrancesco E, et al. The PLAT study: haemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT study group. Progetto Lombardo Ateo-Thrombosis (PLAT) Study Group. Arterioscler Thromb 1992; 12: 1063-1070.
115. Bovill EG, Bild DE, Hesis G, et al. White blood cell counts in persons aged 65 years or more from the cardiovascular health study: correlations with baseline clinical and demographic characteristics. Am J Epidemiol 1996; 143: 1107-1115.
116. Qi H, Koyama T, Kishida K, Miyasaka N, Hirosawa S. Urinary procoagulant activity and tissue factor levels in patients with diabetes mellitus. Haemostasis 1997; 27: 57-64.
117. Tipping PG, Dowling JP, Holdsworth SR. Glomerular procoagulant activity in human proliferative glomerulonephritis. J Clin Invest 1988; 81: 119-125.
118. Silva FG, Hoyer J, Pirani CL. Sequential studies of glomerular crescent formation in rats with anti-glomerular basement membrane-induced glomerulonephritis and the role of coagulation factors. Lab Invest 1984; 53: 404-415.
119. Winter H, Majid NH. Glomerulonephritis - an emerging disease? Vet Bull 1984; 54: 327-335.
120. Wajsman Z, Merrin CE, Chu MT, Moore RH, Murphy GB. Evaluation of biological markers in bladder cancer. J Urol 1975; 114: 879-883.
121. Martinez-Pinerio JA, Pertusac C, Maganto E, et al. Urinary fibrinogen degradation products (FDP) in bladder cancer. Eur Urol 1978; 4: 348-350.
122. Lwaleed BA, Chisholm M, Francis JL. Urinary tissue factor levels in controls and patients with cancer (Abstract). Br J Cancer 1997; 75: 16.
123. Spillert CR, Lazaro EJ. Shortened endotoxin-activated clotting time in patients with carcinoma. Am Surg 1987; 53: 164-166.
124. Østerud B, Olsen JO, Wilsgard L. The role of arachidonic acid release and lipoxygenase pathway in lipopolysaccharide-induced thromboplastin activity in monocytes. Blood Coagul Fibrinol 1990; 1: 41-46.
125. Edwards RL, Levine JB, Green R, et al. Activation of blood coagulation in Crohn's disease: increased fibrinopeptide A levels and enhanced generation of monocytes tissue factor activity. Gastroenterology 1987; 92: 329-337.
126. Lwaleed BA, Francis JL, Chisholm M. Urinary tissue factor in urological cancer. Associations with tumour presence and progression (Abstract). Br J Haematol 1998; 102: 264.